| Treatmentc
| Level of significance |
---|
Control | T1 | T2 | T3 |
---|
IMF (%) | 1.90 ± 0.80 | 2.90 ± 1.22 | 2.66 ± 0.23 | 2.78 ± 0.99 | NS |
Fatty acids |
SFA (%) | 43.7 ± 0.35a
| 43.6 ± 0.61a
| 43.2 ± 0.59a
| 41.5 ± 0.81b
| * |
MUFA (%) | 44.1 ± 0.63 | 44.4 ± 1.01 | 43.7 ± 0.80 | 45.0 ± 1.22 | NS |
PUFA (%) | 12.1 ± 0.21b
| 12.0 ± 0.45b
| 13.1 ± 0.55a
| 13.6 ± 0.65a
| * |
PUFA:SFA | 0.28 ± 0.02b
| 0.28 ± 0.02b
| 0.30 ± 0.01ab
| 0.33 ± 0.01a
| * |
n-6 (%) | 11.6 ± 0.97 | 11.4 ± 1.79 | 12.4 ± 1.51 | 12.9 ± 0.41 | NS |
n-3 (%) | 0.57 ± 0.06 | 0.58 ± 0.10 | 0.67 ± 0.14 | 0.68 ± 0.15 | NS |
n-6:n-3 | 20.3 ± 1.31 | 19.7 ± 1.37 | 18.7 ± 1.93 | 19.6 ± 4.61 | NS |
h/H index | 1.78 ± 0.07b
| 1.83 ± 0.07b
| 1.91 ± 0.11b
| 2.09 ± 0.12a
| ** |
Cholesterol (mg/100 g) |
Total cholesterol | 99.1 ± 1.46a
| 96.4 ± 0.97ab
| 98.1 ± 2.60ab
| 94.4 ± 2.46b
| * |
HDL cholesterol | 25.3 ± 1.23 | 29.4 ± 3.60 | 29.2 ± 0.39 | 25.5 ± 1.61 | NS |
LDL cholesterol | 51.4 ± 1.40a
| 45.2 ± 3.13b
| 46.6 ± 1.40b
| 47.4 ± 1.52b
| * |
-
cControl: basal diet; T1: basal diet with 0.3 % PP powder; T2: basal diet with 0.6 % PP powder; T3: basal diet with 0.9 % PP powder
- Results are expressed in mean value ± SD
- Levels of significance: NS = not significant; *P < 0.05; **P < 0.01
-
a-bMeans within a row with different superscripts differ significantly (P < 0.05)
-
Abbreviations: SFA saturated fatty acid, MUFA monounsaturated fatty acid, PUFA polyunsaturated fatty acid, n-6 sum of linoleic (C18:2n-6) γ-linolenic (C18:3n-6), eicosadienoic (C20:2n-6), and arachidonic (C20:4n-6) acids, n-3 sum of α-linolenic acid (C18:3n-3), eicosatrienoic acid (C20:3n-3), EPA (C20:5n-3), and DHA (C22:6n-3), n-6:n-3 ratio of n-6 to n-3, h:H index ratio of hypocholesterolemic to hypercholesterolemic potential [h/H = (18:1n-9 + 18:2n-6 + 20:4n-6 + 18:3n-3 + 20:5n-3 + 22:5n-3 + 22:6n-3)/(14:0 + 16:0)], HDL high-density lipoprotein, LDL low-density lipoprotein